Monitoring during gonadotrophin-releasing hormone antagonist protocols

Human Fertility

Volumn 5, Issue 1, 2002, Pages

  Fleming, Richard ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN;

BIOSYNTHESIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENDOCRINOLOGY; FEMALE INFERTILITY; HORMONE RELEASE; HUMAN; LUTEINIZATION; MENSTRUAL CYCLE; MONITORING; MULTICENTER STUDY; OOCYTE; OVARY; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; REPRODUCTION; SHORT COURSE THERAPY;

EID: 0036127833     PISSN: 14647273     EISSN: None     Source Type: Journal    
DOI: 10.1080/1464727992000199791     Document Type: Conference Paper

References (15)

1. Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin
2. Factors regulating the growth of the pre-ovulatory follicle in sheep and humans
3. Comparison of fertilization, cleavage and pregnancy rates of oocytes from large and small follicles
4. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon)
5. Relationship of human follicular diameter with oocyte fertilization and development after in vitro fertilization or intracytoplasmic sperm injection
6. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation
7. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial
8. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression
9. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
10. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation
11. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers
12. Fourier transform infrared spectroscopy of follicular fluids from large and small antral follicles
13. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI
14. A prospective randomized study of the optimum timing of human chorionic gonadotrophin administration after pituitary desensitisation in in vitro fertilisation
15. Doubling the human menopausal gonadotrophin dose in the course of an in vitro fertilization treatment cycle in low responders: A randomized study